Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

Pharmacogenomics Journal

Volumn 11, Issue 4, 2011, Pages 274-286

  Wang, D ^a   Guo, Y ^b   Wrighton, S A ^b   Cooke, G E ^c   Sadee, W ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

allelic expression imbalance; CYP3A4; cytochrome P450; gene expression; polymorphism; statin

Indexed keywords

ATORVASTATIN; CIS ACTING ELEMENT; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MEVINOLIN; PREGNANE X RECEPTOR; RETINOID X RECEPTOR ALPHA; RNA; SIMVASTATIN; TRIACYLGLYCEROL;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG POTENCY; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INTRON; LIVER; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE;

ALLELIC IMBALANCE; CYTOCHROME P-450 CYP3A; DYSLIPIDEMIAS; HAPLOTYPES; HEP G2 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRONS; LIPIDS; LIVER; LOGISTIC MODELS; ODDS RATIO; OHIO; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, HETEROGENEOUS NUCLEAR; RNA, MESSENGER; TRANSFECTION; TREATMENT OUTCOME;

EID: 79960633918     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.28     Document Type: Article

References (58)

1. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002; 3: 561-597. (Pubitemid 35331660)
2. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31: 755-761. (Pubitemid 36617664)
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423. (Pubitemid 24229655)
4. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 50-upstream regulatory region. Biochem Biophys Res Commun 1999; 259: 201-205. (Pubitemid 29264018)
5. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-1294. (Pubitemid 35284253)
6. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373-388. (Pubitemid 30433571)
7. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36: 169-181.
8. He P, Court MH, Greenblatt DJ, von Moltke LL. Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol 2006; 46: 1356-1369. (Pubitemid 44564365)
9. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005; 6: 369-383. (Pubitemid 41086769)
10. Takagi S, Nakajima M, Mohri T, Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 2008; 283: 9674-9680.
11. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009; 37: 2112-2117.
12. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-1229. (Pubitemid 28407089)
13. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006; 2: 171-182. (Pubitemid 46372363)
14. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121-132. (Pubitemid 34298916)
15. Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, Raunio H et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002; 71: 196-204. (Pubitemid 34271123)
16. Amirimani B, Walker AH, Weber BL, Rebbeck TR. RESPONSE: remodification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91: 1588-1590.
17. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12: 355-366. (Pubitemid 34816415)
18. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P et al. Population distribution and effects on drug metabolism of a genetic variant in the 50. promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66: 288-294. (Pubitemid 29451761)
19. Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 2004; 64: 8461-8467. (Pubitemid 39491788)
20. Miao J, Jin Y, Marunde RL, Kim S, Quinney S, Radovich M et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J 2009; 9: 319-326.
21. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391. (Pubitemid 32268418)
22. Matsumura K, Saito T, Takahashi Y, Ozeki T, Kiyotani K, Fujieda M et al. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol 2004; 65: 326-334. (Pubitemid 38134260)
23. Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C et al. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J 2009; 9: 49-60.
24. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nurnberg P et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 2007; 8: 443-453. (Pubitemid 46746352)
25. Hirota T, Ieiri I, Takane H, Maegawa S, Hosokawa M, Kobayashi K et al. Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum Mol Genet 2004; 13: 2959-2969. (Pubitemid 39585228)
26. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105. (Pubitemid 44301483)
27. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-160. (Pubitemid 36835963)
28. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005; 78: 551-558. (Pubitemid 41698910)
29. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93: 104-107. (Pubitemid 38022047)
30. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008; 64: 877-882.
31. Becker ML, Visser LE, Van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 2010; 19: 75-81.
32. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-732.
33. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C4T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704. (Pubitemid 41345321)
34. Pinsonneault J, Nielsen CU, Sadee W. Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther 2004; 311: 1088-1096. (Pubitemid 39612715)
35. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
36. Dai Z, Papp AC, Wang D, Hampel H, Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 2008; 1: 24.
37. Papp AC, Pinsonneault JK, Cooke G, Sadee W. Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. Biotechniques 2003; 34: 1068-1072. (Pubitemid 36554575)
38. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP et al. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 2005; 314: 626-635. (Pubitemid 41043843)
39. Kolwankar D, Vuppalanchi R, Ethell B, Jones DR,Wrighton SA, Hall SD et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol 2007; 5: 388-393. (Pubitemid 46401527)
40. Giacopelli F, Rosatto N, Divizia MT, Cusano R, Caridi G, Ravazzolo R. The first intron of the human osteopontin gene contains a C/EBP-betaresponsive enhancer. Gene Expr 2003; 11: 95-104. (Pubitemid 36875505)
41. Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T et al. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006; 45: 1143-1154. (Pubitemid 44763442)
42. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112: 1013-1021.
43. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38: 978-988. (Pubitemid 37221681)
44. Vyhlidal CA, Gaedigk R, Leeder JS. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos 2006; 34: 131-137. (Pubitemid 43042654)
45. Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 2002; 42: 1-23. (Pubitemid 34160517)
46. Michlewski G, Sanford JR, Caceres JF. The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell 2008; 30: 179-189. (Pubitemid 351626689)
47. Lemaire R, Prasad J, Kashima T,Gustafson J, Manley JL, Lafyatis R. Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins. Genes Dev 2002; 16: 594-607. (Pubitemid 34212492)
48. Baralle M, Pastor T, Bussani E, Pagani F. Influence of Friedreich ataxia GAA noncoding repeat expansions on pre-mRNA processing. Am J Hum Genet 2008; 83: 77-88.
49. Buratti E, Brindisi A, Pagani F, Baralle FE. Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance. Am J Hum Genet 2004; 74: 1322-1325. (Pubitemid 38669335)
50. Grabczyk E, Usdin K. The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res 2000; 28: 2815-2822. (Pubitemid 30488540)
51. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004; 75: 1059-1069. (Pubitemid 39534403)
52. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005; 338: 299-305. (Pubitemid 41540570)
53. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341. (Pubitemid 28182231)
54. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410-415. (Pubitemid 27195943)
55. Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta 2008; 398: 15-20.
56. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14: 523-525. (Pubitemid 39100004)
57. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008; 38: 1240-1251.
58. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 2009; 10: 1017-1024.